Opening the Window: A Feedback-Loop Reanalysis of Antiglucocorticoid Trial Failures and a Combined Protocol for Belief Revision in Stress-Locked Psychiatric Disorders

Three decades of antiglucocorticoid trials — spanning glucocorticoid receptor (GR) antagonists, cortisol synthesis inhibitors, and CRH receptor antagonists across multiple psychiatric disorders — show a consistent pattern: biological engagement of the HPA axis, cognitive improvement in prefrontal-dependent functions, subgroup benefit, and population-level failure on primary symptom endpoints. This paper proposes that the recurrent failure reflects incomplete intervention logic rather than a wrong hypothesis. A feedback-loop model identifies cortisol elevation as a dynamic component of a self-reinforcing cycle: chronic stress elevates cortisol, cortisol impairs prefrontal function, impaired prefrontal function prevents belief revision, maintained maladaptive attributions regenerate stress, and the loop perpetuates itself. Pharmacological cortisol modulation opens a temporal window of restored prefrontal function — demonstrated by sustained cognitive improvements in mifepristone trials — but no trial delivered structured therapeutic work during this window. The paper synthesizes evidence across all three drug classes, identifies the MR/GR rebalance mechanism underlying the cognitive window, and proposes a proof-of-concept study testing whether mifepristone enhances attributional flexibility — not only executive function — during the post-cessation window (days 8–21). Patient-selection criteria, validated outcome measures (Reflective Functioning Questionnaire, Cognitive Flexibility Inventory), and falsification conditions are specified. If attributional flexibility does not increase during the window despite documented cognitive improvement, the mechanistic link between cortisol modulation and belief revision is disconfirmed. The proposal is positioned within the emerging class of pharmacologically augmented therapeutic windows, alongside D-cycloserine-augmented exposure therapy.